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ABSTRACT 
Eicosanoids are critical mediators of 
fever, pain and inflammation generated by 
immune and tissue cells.  We recently described a 
new bioactive eicosanoid generated by 
cyclooxygenase-1 (COX-1) turnover during 
platelet activation that can stimulate human 
neutrophil integrin expression. On the basis of 
mass spectrometry (MS/MS and MS3), stable 
isotope labeling and GC/MS analysis, we 
previously proposed a structure of 8-hydroxy-
9,11-dioxolane eicosatetraenoic acid (DXA3). 
Here, we achieved enzymatic synthesis and 1H-
NMR characterization of this compound with 
results in conflict with the previously proposed 
structural assignment. Accordingly, by using LC-
MS, we screened autoxidation reactions of 11-
HpETE and thereby identified a candidate 
sharing the precise reverse phase 
chromatographic and MS characteristics of the 
platelet product. We optimized these methods to 
increase yield, allowing full structural analysis by 
1H-NMR. The revised assignment is presented 
here as 8,9-11,12-diepoxy-13-hydroxy-
eicosadienoic acid, abbreviated to 8,9-11,12-
DiEp-13-HEDE or DiEpHEDE, substituted for 
the previous name DXA3. We found that in 
platelets, the lipid likely forms via dioxolane ring 
opening with rearrangement to the diepoxy 
moieties, followed by oxygen insertion at C13.  
We present its enzymatic biosynthetic pathway 
and MS/MS fragmentation pattern, and using the 
synthetic compound, demonstrate that it has 
bioactivity. For the platelet lipid, we estimate 16 
isomers based on our current knowledge (and 4 
isomers for the synthetic lipid). Determining the 
exact isomeric structure of the platelet lipid 
remains to be undertaken. 
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Platelets regulate innate immunity during 
acute infection and injury through their inter- 
actions with leukocytes (1-3). These cells 
generate lipid mediators, including eicosanoids 
such as thromboxane A2 (TXA2), 12-
hydroxyeicosatetraenoic acid (12-HETE) and 
lesser amounts of prostaglandins (PGs) PGE2.  
Recently, we examined whether platelets 
release leukocyte-regulating lipids using a 
lipidomic approach and uncovered a new 
eicosanoid formed via COX-1 or COX-2 
oxidation of arachidonate (4,5).  Based on 
extensive biochemical evidence including 
MS/MS of the platelet lipid compared with 
synthetically generated stable isotope-labelled 
analogs, the structure of 8-hydroxy-9,11-
dioxolane eicosatetraenoic acid (DXA3) was 
initially proposed. We also used GC/MS, and 
demonstrated generation of an analogous lipid 
using purified recombinant COX isoforms. A 
pathway to chemically synthesized lipid via 11-
HpETE oxidation was shown, consistent with 
previous reports for cholesteryl-dioxolanes (6,7). 
A structure and mechanism of formation was 
suggested based on our findings. At that time, we 
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did not have sufficient quantities of purified 
synthetic lipid for NMR and had to rely on 
analysis of semi-purified synthetic lipid from low 
yield reactions only.   
To obtain more definitive evidence, we 
next attempted to generate the proposed 
dioxolane structure using total synthesis 
approaches. However, this was not successful. 
Instead herein, this was achieved through 
enzymatic oxidation of preformed EETs to form 
two candidate molecules.  However, NMR 
analysis of these found that dioxolane lipids did 
not match the platelet isomer.  As an alternative 
strategy, we next focused on modifying and 
scaling up the chemical oxidation approach to 
yield a lipid that is consistent with the platelet 
isomer in terms of MS/MS and reverse phase 
retention time. We refer to this herein as the 
“synthetic” lipid (which contains one primary 
lipid and small amounts of two additional 
isomers).  Once isolated, 1NMR and COSY 
analysis was undertaken.  The nature of 
functional groups was revealed, along with 
position and geometry for both epoxides and one 
double bond.  This data is presented in full 
herein.  In summary, based on our data, the 
“platelet” lipid is proposed as a further stable 
metabolite of COX-1, generated likely via ring 
opening of the dioxolane ring followed by 
rearrangement and further oxygen insertion.  The 
new structure is presented here as 8,9-11,12-
DiEp-13-HEDE (DiEpHEDE), a di-epoxy-
monohydroxy eicosadienoic acid, which is 
generated by COX-1 in human platelets.  
 
 
Results 
 
Synthesis and purification of DXA3 from 
oxidation of EETs 
First, we attempted to generate the 
proposed structure of DXA3, through oxidation of 
EETs using a recombinant LOX. In this way, two 
diastereomers were generated by oxidation of 
8S,9R-EET and 8R,9S-EET using recombinant 
8R-LOX (8) forming specifically the cis-
endoperoxide product 8S,9S,11R (from 8S,9R-
EET) and trans-endoperoxide product 
8R,9R,11R (from the enantiomer, 8R,9S-EET).  
1H-NMR confirmed the structures of these lipids, 
as shown for the cis, 8S,9S,11R, and both 
showed expected conjugated diene UV spectra 
(Figure 1, 2). These were then compared using 
reverse phase LC/MS/MS with the COX-1 
derived lipid.  However, they eluted later, and 
while their MS/MS spectra had some common 
fragment ions (labeled in red), they contained 
additional large ions that were absent in MS/MS 
spectra from the COX-1 derived lipid.  In 
particular, these hydroxy-endoperoxides 
generated large daughter ions at m/z 185 quite 
distinct from the fragmentation properties of the 
platelet product (Figure 2). Thus these dioxolanes 
were inconsistent with the platelet lipid and 
additional candidates were sought as described 
below.  
 
Scaling up generation via arachidonate 
oxidation, termed “synthetic lipid”. 
We previously generated small amounts 
of the “synthetic lipid”, by oxidation of 11-
HpETE, as outlined by Porter et al, for 
synthesizing cholesteryl ester dioxolane 
derivatives (6,7).  This lipid, which has the same 
MS/MS and reverse phase retention time as the 
platelet isomer was sufficient for MS/MS 
analysis, but the produced amounts were not 
enough to provide good NMR data.   
Herein, we modified this method based 
on observing that the synthetic lipid forms even 
during the oxidation of arachidonic acid, while 
making 11-HpETE. In this way, the scaling up 
was simplified to a single process.  Despite the 
fact that yields were quite low using this method 
(<0.05%), we managed to isolate the synthetic 
lipid in the amounts (around 400 µg), which were 
enough for further analysis.  While large numbers 
of oxidized lipids are present in this crude 
reaction mixture, only one matched the platelet 
lipid’s MS/MS spectrum and retention time 
(labeled Peak B in Figure 3).  A full description 
of the purification is presented under 
Experimental Procedures.  
It should be noted that all biologically 
active eicosanoids would be expected to form at 
low yield in a complex and uncontrolled free 
radical oxidation system such as this.  If we 
consider a lipid such as PGE2, we expect that it 
would be present in such a reaction but at 
similarly low yield to what we found here, in 
addition to literally hundreds of other oxidation 
products. 
The lipid matching the platelet lipid 
based on MS/MS and retention time was targeted 
for further purification and characterization in 
this report as follows, and is identified as the 
synthetic lipid previously characterized in our 
earlier study(4).  Specifically, oxidized lipids 
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were separated using normal phase 
chromatography, with several products visible at 
206 nm (Figure 3 A, labeled A-D).  Fractions 
were collected and analyzed using high 
resolution Orbitrap MS/MS, and compared to 
platelet lipid (purified from activated platelets 
using reverse phase LC).  Peak B was found to 
have the same Orbitrap MS/MS and was further 
purified using reverse phase HPLC and is thus 
identified as the synthetic lipid (Figure 3 B,C). 
Synthetic lipid was next compared with the 
platelet lipid using a longer UPLC-MS/MS 
method for further structural confirmation. First, 
a Q1MS scan of the synthetic lipid shows a 
prominent peak around 47 min indicating the 
most abundant component (Figure 4 A). Small 
peaks eluting immediately before and after are 
noted, as we previously published for the 
synthetic lipid generated using 11-HpETE 
oxidation, and are likely diastereomers (4).  Next, 
both synthetic and platelet lipids were monitored 
using parent m/z 351.2 fragmenting to daughter 
ion m/z 165.  Again, peak B/synthetic lipid 
comprises one predominant isomer, with two 
smaller peaks eluting immediately before and 
after while the platelet lipid is a single peak 
(Figure 4 B).  These three isomers in the 
synthetic lipid preparation have identical MS/MS 
spectra and likely represent quantitatively minor 
diastereomers of the platelet lipid, as previously 
reported (data not shown) (4).  Importantly, low 
resolution MS/MS spectra acquired at the apex of 
the peak at 47.5 min, using a tandem quadrupole 
instrument are virtually identical (Figure 4 C,D).  
The synthetic and platelet lipids were next 
compared using straight phase HPLC.  Here, the 
synthetic lipid shows a slightly later retention 
time to the platelet isomer (Figure 4 E).  This 
indicates the lipids are likely different 
stereoisomers of the same compound.  Peak B, as 
purified from Figure 3 B was then taken forward 
for NMR analysis to inform us about the 
potential structure of the platelet lipid.  
 
NMR analysis of synthetic lipid identifies 
structure as 8,9-11,12-DiEp-13-HEDE 
Structure elucidation of synthetic lipid as 
8,9-11,12-DiEp-13-HEDE was achieved via 1H-
NMR and COSY. For structure numeration and 
assignment, refer to Figure 5 A,B, 6 A and Table 
1. Preliminary determination began with the 
identification of H13, which was assigned based 
on the 1H-NMR of a similar compound obtained 
by Brash(9). Upon identification of the H13 
proton, assignment of the epoxide and olefinic 
protons was possible based on 1H-1H correlations 
acquired from the COSY spectrum shown in 
Figure 6 B, and Table 1. Correlations are 
observed from H13 to the H14 olefinic proton 
and to the epoxide proton H12 allowing 
assignment of these protons. H14 is correlated 
with the most downfield olefinic proton, which 
was assigned as H15, and the olefin 1H-1H 
coupling of 11Hz confirms that this double bond 
has the Z-configuration (Figure 5 A). This allows 
the assignment of the peaks between H14 and 
H15 as the two other olefinic protons.  However, 
protons H5 and H6 are unassigned since their 
signals appear as multiplets (Figure 5 A). Given 
the structure of the AA substrate used to generate 
the synthetic lipid, we propose cis geometry for 
the double bond at 5,6.   
  These protons are coupled to methylene 
CH2 protons H4 and H7 (Figure 6B, Table 1). 
H13 shows correlation to H12 (integrating at 
~3.0) at 2.83 ppm, which leaves the single proton 
at 2.99 ppm to be H11 or H9 (Figure 6B, Table 
1). Correlation from the H10 protons to two 
epoxide protons suggests the final structure as the 
methylene bridged diepoxide shown (Figure 6 B, 
6 C, Table 1). In summary, we propose that both 
epoxy rings are located in positions 8,9 and 11,12 
where the double bonds of AA were originally 
sited.  
Even though assignment of the 1H-NMR 
and the COSY in CD3OD allowed us to obtain a 
general structure, we were interested in gathering 
additional structural information about the 
relative stereochemistry of some functional 
groups in our molecule as was done previously 
(10).  Initial attempts to assign relative 
stereochemistry between the hydroxyl and 11,12-
epoxide via measurement of J couplings were 
unsuccessful due to the overlap of epoxide 
protons.  Although the synthetic lipid was 
completely insoluble in benzene, a 90:10 mix of 
benzene-d6: methanol-d4 was found to yield a 
proton spectrum in which these epoxide protons 
were completely separated (Figure 5 B, 6 A). 
Here, we acquired a proton spectrum that 
resolved the assignment and J couplings for 
these. As shown in Figure 5 B, protons in the 
positions 8 and 9 as well as 11 and 12 contained a 
small coupling constant in the range of 2.1-2.3Hz 
which is consistent with trans-configuration of 
epoxy rings(9). Thus, on the basis of the 2 Hz 
coupling constants, the NMR analysis defines 
both the 8,9- and 11,12-epoxide groups as trans-
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epoxy, but their absolute stereochemistry has not 
been established. 
To summarise our NMR data, the 
synthetic lipid is shown to be 8,9-11,12-diepoxy-
13-hydroxy-eicosadienoic acid using NMR and 
MS/MS.  Furthermore, NMR proves the position 
of the double bond at 14,15, with cis geometry.  
NMR also proves that the relative configuration 
of the hydroxyl group at 13 and the adjacent 
carbon atom of epoxy ring at 11,12 is trans. 
Overlapping multiplets for H5 and H6 prevented 
unambiguous assignment of this double bond 
configuration.  However, based on the structure 
of AA, we propose that the double bond located 
at 5,6 has cis geometry.  Both epoxy rings are 
confirmed as trans configuration.  We can’t 
determine the absolute configuration of the 
hydroxyl group and both epoxy rings from our 
NMR data. However, the epoxides will be either 
S,S or R,R, while the hydroxyl will be the same 
configuration as the epoxy ring at position 11,12. 
Thus, the list of likely structures for the synthetic 
lipid includes: 8(R),9(R)-trans-11(R),12(R)-
trans-DiEp-13(R)-HEDE, 8(S),9(S)-trans-
11(R),12(R)-trans-DiEp-13(R)-HEDE, 8(R),9(R)-
trans-11(S),12(S)-trans-DiEp-13(S)-HEDE, 
8(S),9(S)-trans-11(S),12(S)-trans-DiEp-13(S)-
HEDE, with both double bonds predicted as cis. 
With the amount of lipid we were able to 
generate using our current synhtetic approach, 
NMR studies are unable to distinguish the 
absolute configuration further than this. The 
proposed structure is shown as Figure 6 C, and is 
also informed by the data in Schneider et al, in 
which the initial epoxide relative stereochemistry 
is set via the 9,11-endoperoxide intermediate (9).  
 
Proposed MS/MS fragmentation for 
DiEpHEDE 
Overall, our new data showing identical 
MS/MS and reverse phase retention time to the 
synthetic lipid generated here confirms the 
platelet lipid to be 8,9-11,12-diEp-13-HEDE, 
while different chiral LC retention time indicated 
that the synthetic and platelet lipids are different 
isomers. We next considered which candidate 
isomers are most likely for the platelet lipid. 
Given the presence of cis double bonds in AA, 
and that COX enzymes generate 13(R) 
hydroperoxyl/hydroxyl isomers during turnover, 
we predict that the platelet lipid forms in line 
with these structural features.  Given this, we 
propose that there are 16 potential isomers for the 
platelet lipid.  This is based on the potential for 
cis or trans epoxides and resulting 
stereochemical configurations possible (Figure 6 
D).  Unfortunately, a total synthetic approach to 
generate all 16 would take several years and is 
beyond the scope of this current study.  We note 
that Schneider previously showed a cis epoxide at 
9,10, and trans at 12,13 for a 8,9-11,12-diEp-13-
HEDE isomer generated by a mutant COX-2 
isoform (9), however without further evidence for 
this configuration in the platelet lipid we have not 
assigned this geometry (see discussion for more 
detail on this).  
Next, based on our findings, the MS/MS 
fragmentation route previously presented for the 
platelet lipid, based on extensive high resolution 
MS/MS of native and deuterated analogs and 
MS3 was reevaluated.  Most daughter ions 
mapped to similar fragmentation routes, and all 
major ions could be assigned to this the structure, 
including m/z 195 which could not previously be 
accounted for (Supplemental Schemes). Possible 
mechanisms involved in the formation of m/z 
255, 207, and 163 are presented in Supplemental 
Scheme 1, as well as mechanisms for m/z 333, 
and 289 (Supplemental Scheme 2), m/z 183 and 
139 (Supplemental Scheme 3), m/z 195 and 177 
(Supplemental Scheme 4), and m/z 315 and 271 
(Supplemental Scheme 5). All of the proposed 
reaction pathways taking place in the gas-phase 
after collisional activation have been previously 
described for epoxy fatty acids and proposed 
fragment ions are consistent with the high-
resolution mass spectrometric measurements and 
deuterium labeled analog previously published 
(4,10). 
 
8,9-11,12-diEp-13-HEDE activates leukocyte 
integrin expression.  
We previously found that a semi-purified 
platelet-derived DiEpHEDE isomer can activate 
neutrophil integrin expression (4).  To investigate 
whether synthetic 8,9-11,12-diEp-13-HEDE 
retained the same property as the platelet isomer, 
we repeated the experiment on three separate 
donor isolates as shown using the synthetic lipid 
(Figure 7 A, B).  In our earlier study, we also 
found that DiEpHEDE can stimulate priming of 
neutrophils at far lower amounts of 10 nM.  
Herein we repeated this several times, but it was 
not consistent in all donor isolations, being only 
observed in around 50 %. This suggests reduced 
potency of the synthetic lipid, and is also 
consistent with it being a different isomer.   
 
	 	
Generation of a diepoxy-eicosanoid by cyclooxygenase-1		
		 5	
Discussion 
We recently identified a new lipid 
generated by COX-1 in human platelets that can 
activate neutrophils and proposed the structure as 
8-hydroxy-9,11-dioxolane eicosatetraenoic acid 
based on extensive biochemical and chemical 
evidence, but without NMR (4).  We now present 
1H and COSY NMR data, which revises the 
structure to 8,9-11,12-DiEp-13-HEDE, a 
metabolite that we suggest forms in platelets 
through opening of an initially formed dioxolane 
ring followed by epoxidation, oxygen insertion 
and reduction as explained in detail below 
(Figure 6 D).  Based both on the biology of 
COX-1 and structure of the substrate AA, we 
propose that the primary synthetic lipid is one of 
4 potential isomers, while the platelet lipid is one 
of 16, noting that the platelet isomer is not 
present in the synthetic lipid preparation.  This is 
evidenced by the two lipids having different 
retention time on chiral phase chromatography 
(Figure 4 E) 
Herein, we tested the ability of the 
synthetic lipid to either activate (directly) or 
prime neutrophils in response to the bacterial 
peptide fMLP, for MAC-1 activation. In the case 
of priming, the lipid is added first, at far lower 
concentrations and then the ability of fMLP to 
activate is tested following a pre-incubation step.   
In our previous study, we showed that the platelet 
lipid could activate directly at 10 µM, while it 
also primed at 10 nM (4). Here, the synthetic 
lipid showed an ability to activate neutrophils, 
however for priming it was less effective than we 
previously observed with the platelet lipid.  It is 
well known that in terms of lipid signalling, 
isomeric structure is critical to biological 
function (e.g. recognition by GPCRs).  This is 
similar to prostaglandins and their enantiomers 
(isoprostanes), which show similarities, but also 
reduced potency in signalling ability Thus, the 
synthetic lipid may be less bioactive, leading it to 
behave differently to the platelet isomer in 
bioassays at extremely low concentrations. We 
expect that the amounts of DiEpHEDE generated 
by platelets will be sufficiently high for 
signalling at low concentrations. Specifically, we 
detected generation of around 6 ng/108 cells, 
while at the same time there was 1.6ng PGE2 and 
25 ng TXB2(4).  Importantly, despite lower 
amounts of PGE2, this lipid is well known to be 
bioactive towards platelets (11).  This indicates 
that a platelet eicosanoid generated in lower 
amounts than DiEpHEDE is already known to be 
bioactive, providing confidence that DiEpHEDE 
is generated in biologically-relevant amounts, 
while noting that generation of this lipid in 
platelets is sensitive to aspirin(4).  While we have 
not tested the mechanism of action, activation of 
BLT receptors that are activated by leukotrienes 
is one possibility.  
Lipids generated by vascular cells can 
possess multiple bioactivities and an exhaustive 
examination (e.g. vaso constriction, activation of 
platelets, leukocytes to express integrins, 
degranulate, mobilise calcium, shape change, 
phagocytose, aggregate, etc) would be out of the 
scope of this study. 
Previously, we demonstrated that the 
platelet lipid can be synthesized by COX-1 in 
intact cells or by recombinant COX-1 or -2 in 
vitro (2).  A mechanism was proposed whereby a 
9,11-dioxolane lipid with carbon-centered radical 
at C8 exited the active site then reacted with O2 
before reduction to form the product.  In those 
studies, we established that the dioxolane ring 
forms before lipid exiting the active site using 
mutant COX-2 enzymes, thus using this 
information we now present a revised route to 
formation of 8,9-11,12-diEp-13-HEDE taking 
this into account as follows (Scheme 1): (i) 9,11-
dioxolane with carbon-centered radical at C8 
exits active site, (ii) intramolecular attack by the 
C8 radical on the dioxolane leads to ring opening 
and reaction by the oxygens on C8 and C12, 
forming di-epoxides, and leaving a carbon 
centered radical at C13.  This then reacts with O2, 
before reduction to the 13-hydroxy lipid.   While 
the mechanism in Figure 8 suggests that the lipid 
radical exits the active site, another possibility is 
that the second diatomic oxygen attacks while in 
the active site, similar to the mechanism by 
which the endoperoxide, PGG2, is formed in the 
cyclooxygenase pathway. The platelet lipid 
appears as a single isomer on chiral and reverse 
phase HPLC, which means that the formation of 
this lipid is stereochemically controlled.  This led 
us to propose that the dioxolane is formed prior 
to radical exit.   
Formation of di-epoxy-eicosanoids by 
COX-2 isoforms has been reported previously 
(9).  Thus, we had previously considered these as 
potential candidates for the platelet lipid. 
However, they were discounted based on several 
lines of evidence, in favour of the dioxolane at 
that time, as follows: 
1. Only some mutant COX-2 isoforms have been 
shown to generate di-epoxy-eicosanoids, 
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including 8,9-11,12-DiEp-13-HEDE.  In 
previous studies, both wild type COX-2 and 
the W387F mutant used herein were unable to 
make the di-epoxide lipid (4,9). As this 
contrasted with our findings where both could 
make this new lipid, we considered that 
specific mutations to the active site are 
required to enable COX isoforms to facilitate 
the exit of the dioxolane followed by ring 
opening and epoxidation.  We consider that 
one potential explanation for our findings was 
down to the use of different extraction 
conditions where in this study we may have 
favoured extraction of more polar products 
such as these, than in the previous work.  
2. During purification of the platelet lipid, a lipid 
with absorbance suggestive of the presence of 
a conjugated diene chromophore eluted from 
the HPLC column (Figure 3 A, B in (4)).  This 
was consistent with the proposed structure of 
“DXA3”, but not with di-epoxides.  LC/UV 
analysis of the purified concentrated 
DiEpHEDE undertaken for this study 
confirms no UV active chromophores are 
present (data not shown).  Thus, we have now 
revisited our raw data from the previous 
study, and determined that the absorbance 
most likely originated from a contaminating 
lipid present in the preparation eluting at the 
same time, also made by platelets.  
Specifically, using MS data from biogenic 
standards we had available at the time of the 
previous study, we can estimate that the 
amount of DiEpHEDE eluting in the peak 
represents around 3.5 µg.  However, based on 
absorbance, the conjugated diene represents 
only 70 ng of product. Thus, given the amount 
of platelet lipid eluting, this UV spectrum is 
too weak to account for the structure 
proposed.    
3. Dioxolane lipids were previously synthesized 
by Porter’s group via oxidation of cholesteryl-
11-HpETE (6,7). In our first study, we 
repeated this reaction using the free acid 11-
HpETE as substrate and detected significant 
amounts of the lipid (4).  This provided proof 
of concept that the 11-hydroperoxyl radical of 
AA can serve as a precursor for the platelet 
lipid, under conditions where dioxolanes are 
known to form in vitro.  This was consistent 
with our proposed mechanism of formation 
via COX isoforms.  
Aside from the UV spectrum presented 
previously (addressed in point 2 above), all our 
structural characterization data previously 
published is directly applicable to the new 
structure and supports the assignment (4).  This 
extensive data includes derivatization and 
GC/MS showing one hydroxyl group, no 
carbonyls, 4 rings/double bonds and two oxygens 
added to arachidonate(4).  Our previous MS/MS 
and MS3 data including stable isotope labeling 
studies are re-interpreted to provide new 
fragmentation pathways, which are fully 
consistent with the structure and synthesis 
pathway (Figure 6 D and Supplemental Schemes 
1-5).  The corrected structure, confirmed to be 
generated by thrombin activated human platelets 
by COX-1, and to activate leukocyte integrin 
expression in vitro is assigned to 8,9-11,12-diEp-
13-HEDE.   
 
Experimental procedures 
 
Materials  
HPLC grade solvents were from Thermo 
Fisher Scientific (Hemel Hempstead, 
Hertfordshire, UK). Anti-human CD11b-Alexa 
Fluor 647 was from BioLegend. All other 
reagents were from Sigma unless otherwise 
stated.  
 
Synthesis of platelet lipid 
Human blood donations were approved 
by the Cardiff University School of Medicine 
Ethics Committee and were with informed 
consent (SMREC 12/37, SMREC 12/10), and 
according to the Declaration of Helsinki. For 
studies on isolated platelets, whole blood was 
collected from healthy volunteers free from non-
steroidal anti-inflammatory drugs for at least 14 
days into acid-citrate-dextrose (ACD; 85 mmol/L 
trisodium citrate, 65 mmol/L citric acid, 
100 mmol/L glucose) (blood:ACD, 8.1:1.9, v/v) 
and centrifuged at 250g for 10 min at room 
temperature. Platelet-rich plasma was collected 
and centrifuged at 900g for 10 min, and the pellet 
resuspended in Tyrode's buffer (134 mmol/L 
NaCl, 12 mmol/L NaHCO3, 2.9 mmol/L KCl, 
0.34 mmol/L Na2HPO4, 1.0 mmol/L 
MgCl2,10 mmol/L HEPEs, 5 mmol/L glucose, 
pH 7.4) containing ACD (9:1, v/v). Platelets were 
centrifuged at 800g for 10 min then resuspended 
in Tyrode's buffer at 2×108 ml−1. Platelets were 
activated at 37 °C in the presence of 1 mmol/L 
CaCl2 for 30 min, with 0.2 U ml−1 thrombin, 
before lipid extraction.  
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Platelet lipid extraction.  
Lipids were extracted by adding a 
solvent mixture (1 M acetic acid, 2-propanol, 
hexane [2:20:30]) to the sample at a ratio of 2.5 
ml solvent mixture to 1 ml sample, vortexing, 
and then adding 2.5 ml of hexane. Following 
vortexing and centrifugation (300 g, 5 minutes), 
lipids were recovered in the upper hexane layer. 
The samples were then re-extracted by the 
addition of an equal volume of hexane followed 
by further vortexing and centrifugation. The 
combined hexane layers were then evaporated to 
dryness using a Rapidvap N2/48 evaporation 
system (Labconco Corporation) and re-suspended 
in 200 µl MeOH. Platelet lipid extract was stored 
at -80 °C until LC/MS/MS analysis. 
 
Synthesis and purification of lipid matching 
COX-1 metabolite from platelets.   
Arachidonic acid was mixed with alpha-
tocopherol (5% by weight) in the round bottom 
flask and oxygen was bubbled through this 
mixture under stirring at 37oC for 3 days. 
Resulting mixture was purified using flash 
chromatography on silica gel (hexane:ethyl 
acetate:acetic acid 90:10:0.5 – 50:50:0.5) and 
fractions were analyzed using high resolution 
LC-MS/MS  (see Figure 3).  Lipids were purified 
using isocratic separation with a mobile phase of 
95:5:0.1 heptane:IPA:acetic acid on a Luna semi-
preparative Silica 5µm 250 x 10 mm column at 5 
mL/min, monitoring at 206 nm (Figure 3A).  A 
second clean-up step utilized an isocratic 
separation of 97:2.5:0.5:0.1 
heptane:IPA:methanol:acetic acid, with a Luna 
silica 5 µm 250 x 4.6 mm at 0.5 mL/min, 
monitoring at 206 nm (Figure 3B).   
 
Synthesis and purification of 8-hydroxy-9,11-
dioxolane eicosatetraenoic acid isomers by LOX 
oxidation of 8,9-epoxyeicosatetraenoic acids.  
  (±)8,9-EET (Cayman) was resolved by 
semi-preparative chiral HPLC (12), and the 
enantiomers each reacted with recombinant P. 
homomalla 8R-lipoxygenase along the lines 
described by Teder et al for other lipoxygenase 
reactions with EETs (13) Briefly, 8,9-EET (50 
µM) was reacted in 0.1 M phosphate pH 8 with 
8R-LOX and the progress followed by UV 
scanning (200 – 350 nm) with appearance of a 
conjugated diene chromophore with lambda-max 
around 240 nm (cf. (13)). Upon complete 
reaction the products were extracted using a 30 
mg Oasis cartridge (Waters), eluted with 
methanol, and subsequently purified by reversed-
phase and normal-phase HPLC. The two main 
products are an 11R-hydroperoxide derivative 
with the 8,9-epoxide moiety still intact (8,9-
epoxy-11R-hydroxy-5Z,12E,14Z-eicosatrienoic 
acid) and the target compound 8-hydroxy-9,11-
endoperoxy-5Z,12E,14Z-eicosatrienoic acid. The 
hydroxy-endoperoxide isomers were generated 
from both 8R,9S- and 8S,9R-EET enantiomers 
and purified as the methyl ester derivatives for 
assignment by 1H-NMR. Subsequently, the free 
acids were isolated and compared by LC-MS 
with the bioactive platelet product. (For 
comparison of 1H-NMR and LC data, an 
equivalent set of derivatives was also prepared by 
8R-LOX reactions with 5,6-EET, providing 5-
hydroxy-6,8-endoperoxy-9E,11Z,14Z-
eicosatrienoic acids; these aided in assigning the 
mass spectral fragmentations of the target 
hydroxy-endoperoxides derived from 8,9-EET). 
NMR data on these lipids is provided in 
Supplementary Data (Supplemental Figure 1).  
 
NMR methods.  
A Varian Unity Inova 400 MHz or 700 
MHz NMR in CD3OD or d-6 Benzene was used 
for di-epoxy compounds. Post-acquisition 
processing was performed in ACD/Spectrus 
processor 2017.2.  1H NMR and 1H,1H COSY 
NMR spectra on the hydroxy-endoperoxides 
were obtained on a Bruker 600 MHz 
spectrometer at 298 K. The parts/million values 
are reported relative to residual nondeuterated 
benzene (C6D6; δ = 7.15 ppm)  All spectra were 
analyzed on Bruker TopSpin 3.0 software.  
 
Straight phase HPLC.  
Lipids were dried then resuspended in 
mobile phase (hexane: 2-propanol:acetic acid, 
90:10:0.1) and injected onto a Chiralcel OD 250 
x 4.6mm column (Chiral Technologies Ltd., 
Exton, PA) with isocratic separation at 1 ml.min-
1. Fractions were collected at 30 sec intervals and 
analysed by direct flow injection monitoring m/z 
351.2 to 165.1 on a tandem quadrupole ion trap 
mass spectrometer (4000 qTrap, Sciex, Thornhill, 
Canada).  
 
Reverse-phase LC-MS/MS.  
LC-MS/MS analysis of human platelet-
derived and synthetic DiEpHEDE was performed 
on a Nexera liquid chromatography system 
(Shimadzu) coupled to by electrospray ionization 
to a tandem quadrupole ion trap mass 
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spectrometer (4000 qTrap, Sciex, Thornhill, 
Canada). Briefly, liquid chromatography was 
performed at 40 °C using a C18 Spherisorb 
ODS2, 5 µm, 150 × 4.6 mm column (Waters, 
Hertfordshire, UK) at a flow rate of 1 ml·min−1 
over 75 min. Mobile phase A was (water, 0.1 % 
formic acid) and mobile phase B was 
(acetonitrile, 0.1 % formic acid). The following 
linear gradient for B was applied: 20 % for 0.5 
min, 20 – 42.5 % over 50 min, 42.5 – 90 % from 
50 to 60 min, and held at 90 % for 5 min 
followed by 10 min at initial condition for 
column re-equilibration. Injection volume was 10 
µL. Ionization was performed using electrospray 
ionization in the negative mode (ESI-), 
monitoring parent ion to daughter ion m/z 351.2 
→ 165.1 (dwell 200 ms), with the following 
parameters:  TEM 650 °C, GS1 70 psi, GS2 55 
psi, CUR 40 psi, ESI spray voltage – 4.3 kV, DP 
− 53 V, EP − 10 V, CE −26 V and CXP at − 7 V. 
Full scan MS was carried out in negative mode 
scanning Q3 from m/z 200 to 600 with total scan 
time (including pauses) over 4 s. Settings were: 
TEM 650 °C, GS1 60 psi, GS2 30 psi, CUR 35 
psi, ESI spray voltage – 4.5 kV, DP − 55 V, EP − 
10 V, CXP at − 30 V and IHE on.  
 
High resolution LC-MS/MS.  
High resolution LC-MS/MS analysis was 
carried out on an Ultimate 3000 UPLC (Thermo 
Scientific) coupled to a Q Exactive mass 
spectrometer (Thermo Scientific).  Mass 
accuracy was determined to be better than 1 ppm. 
Liquid chromatography was performed using 
Phenomenex Kinetex C18 , 2.6µm, 100x2.1mm 
at a flow rate of 400µL·min−1 over 25 min. 
Mobile phases A and B were identical to the 
method above, but with a gradient for B of 15 – 
28 % over 0 to 1 min, 28 – 42% over 1 to 4 min, 
42 – 60 % over 4 to 6 min, 60 – 80 % over 6 to 
16 min, 80 – 95 % over 16 to 19 min, and held at 
95 % over 19 to 22 min followed by 3 min re-
equilibration to 15 %. Injection volume 10µL. 
Electrospray ionization was used in negative 
mode, with a sheath gas flow rate of 60 units, and 
capillary temperature at 320 °C. Data dependent 
MS/MS of m/z 351 was carried out with a 
resolving power of 35,000. 
 
HPLC-UV analysis of COX-1 derived lipid.   
Arachidonic acid was oxidized using 
recombinant ovine COX-1 in vitro. The enzyme 
was incubated with two molar equivalents of 
hematin in 100 mM phosphate buffer for 20 min 
on ice. 3.4 µg COX-1 was incubated with 150 
µM arachidonate and 500 µM phenol in 100 mM 
phosphate buffer for 3 min at 37 °C under 
oxygen atmosphere. Lipids were extracted using 
the hexane-isopropanol-extraction described 
above. Lipids from multiple COX-1 reactions 
were combined and DiEpHEDE was HPLC 
purified employing a Spherisorb ODS2 column 
(5 µm, 150 mm x 4.6 mm; Waters) with LC 
settings and mobile phases described in Reverse-
phase LC-MS/MS. Fractions were collected every 
30 seconds and DiEpHEDE identified by MS/MS 
monitoring m/z 351.2 to 165.1. DiEpHEDE was 
extracted using solid phase extraction using 
silica-based solid phase extraction columns (Sep 
Pak, Waters, MA, USA) which were equilibrated 
with 5 ml of water pH 3.0 followed by 5 ml of 
methanol. The DiEpHEDE sample was diluted 
with water to an organic content of 15 % and 
purified over the column. The column was 
washed with 20 ml water at pH 3.0 and the lipid 
extracted using 5 ml of methanol. Extracts was 
dried using nitrogen flow and the lipid dissolved 
in methanol. About 3.5 µg DiEpHEDE was 
injected on a LC/UV system (Infinity II, Agilent) 
using the same LC settings and absorbance 
measured at 235 nm. 
 
Isolation and activation of human neutrophils  
Human neutrophils were isolated from 
20 ml citrate anticoagulated whole blood and 
resuspended in Krebs buffer. Briefly, blood was 
mixed 1:3 with 2 % trisodium citrate (w/v) and 
HetaSep (Stemcell technologies) and allowed to 
sediment for 45 min at 20 °C. The upper plasma 
layer was recovered and under laid with ice-cold 
Lymphoprep (2:1 for plasma/Lymphoprep) and 
centrifuged at 800 g for 20 min at 4 °C. The 
pellet was resuspended in ice-cold PBS and 0.4 
% sodium tricitrate (wt/vol) and centrifuged at 
400 g for 5 min at 4 °C. Contaminating 
erythrocytes were removed using up to three 
cycles of hypotonic lysis. Finally, cells were 
resuspended in a small volume of Krebs buffer 
(100 mmol/L NaCl, 50 mmol/L HEPES, 
5 mmol/L KCl, 1 mmol/L NaH2PO4, 2 mmol/L d-
glucose, 1.25 mmol/L MgCl2 and 2 mmol/L 
CaCl2, pH 7.4), counted and kept on ice. 
Neutrophils were diluted to 2×106 cells/ml and 
incubated in the presence of DiEHEDE or 
vehicle, for 20 min at 37 °C. In some 
experiments, neutrophils were pre-incubated with 
10 nM DiEpHEDE or vehicle, for 10 min at 37 
°C, and then activated with 10 µM fMLP for a 
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further 10 min at 37 °. Nonspecific antibody 
binding was blocked using 5 % mouse serum in 
ice-cold FACS buffer (PBS containing 0.5 % 
bovine serum albumin (BSA), 5 mmol/L EDTA 
and 2 mmol/L sodium azide, pH 7.4) for 1 h on 
ice and centrifuged at 320 g for 5 min at 4 °C. 
Cells were washed with ice-cold FACS buffer, 
anti-human CD11b-Alexa Fluor 647 or isotype 
control added and incubated for 30 min on ice(4). 
Neutrophils were washed twice with ice-cold 
FACS buffer and analyzed with a FACSCanto II 
flow cytometer (BD Biosciences) and FlowJo 
software. 
 
Statistics  
Data are expressed as mean ± SEM of 
three separate determinations. Statistical 
significance was assessed using one-way 
ANOVA followed by Bonferroni multiple 
comparisons test with Prism software version 7 
(GraphPad). p < 0.05 was considered statistically 
significant. 
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Table 1. COSY assignment of 8,9-11,12-DiE-13-HEDE 1H-1H  gDQCOSY (METHANOL-d4, 400 
MHz) 
	 	
Generation of a diepoxy-eicosanoid by cyclooxygenase-1		
		 13	
 
 
 
Figure 1. 1H-NMR spectrum and COSY analysis of 8S-hydroxy-9S,11R-endoperoxy-
5cis,12trans,14cis-eicosatrienoate Me ester in d6-benzene 
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Figure 2. Comparison of the COX-1 derved lipid with 8-hydroxy-9,11-dioxolanes indicates these are 
different lipids.  Panels A-C. Reverse phase LC/MS/MS indicates that the lipids elute at different retention 
times.  Lipids (COX-1 product, or 8-hydroxy-9,11-dioxolanes were separated using reverse phase 
LC/MS/MS as described in Methods and compared for retention time.  Lipids were detected either as m/z 
351.2 to 165.1 (COX-1 lipid) or to 271.1 (dioxolanes).  Panels D-F. Comparison of MS/MS spectra from 
the COX-1 derived lipid versus in vitro generated dioxolanes, along with confirmation of conjugated diene 
structures for dioxolanes.  MS/MS spectra were acquired at the peak of elution for the lipids shown in 
Panels A-C above.  Ions shown in red for E, F are common to the COX-1 product. Nominal mass is shown 
as these are low resolution spectra (tandem quadruploe mass spectrometer).  Inset UV spectra for the 
dioxolanes were obtained by HPLC-UV analysis as indicated in Methods.   
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Figure 3. Purification and high resolution MS of lipids generated by oxidation of arachidonate, to 
isolate the synthetic lipid.  Panel A. Semi prep normal phase HPLC, as indicated in Methods, with 
collected fractions labeled A-D. The HPLC was monitored online at 206 nm. Panel B. Further HPLC 
purification of peak B (Figure 1A), as indicated in Methods. The HPLC was monitored online at 206 nm.  
Panel C. High resolution  (Orbitrap) LC-MS/MS of platelet lipid (top) versus Peak B (bottom), as indicated 
in Methods.  
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Figure 4. Analysis of platelet lipid and Peak B confirms them to be isomers of the same lipid 
structure. Washed human platelets were activated with 0.2 unit·ml−1 thrombin, for 30 min at 37 °C, and 
lipids extracted. Peak B was generated in vitro and purified as described in Methods. Panel A. Purified 
Peak B was analysed using reverse phase LC/MS/MS on the tandem quadrupole, in full scan mode. Full 
scan was carried out in negative mode, scanning Q3 from m/z 200 to 600.  * shows position of additional 
isomers of Peak B. Panel B. Reverse phase LC/MS/MS of platelet lipid and Peak B showing co-
elution.  Lipids were analyzed using reverse phase LC/MS/MS, monitoring parent m/z 351.2 → 165.1. 
Panels C,D. MS/MS spectra of the lipids obtained with a tandem qudrupole mass spectrometer. Lipids 
were separated as in B and MS/MS spectra acquired at the apex of elution using enhanced product ion 
mode. Nominal mass is shown as these are low-resolution spectra. Panel E. Straight phase HPLC of 
platelet lipid and Peak B show the lipids separate.  Lipids were resuspended in mobile phase and analysed 
as outlined in Methods.  
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Figure 5. H-NMR data of the synthetic lipid in Methanol-d4 and Benzene-d6 shows the structure as 
8,9-11,12-DiEp-13-HEDE.  Panel A.  1H NMR (METHANOL-d4, 400 MHz) δ 5.60 (dtd, 1H, J=1.17, 
7.54, 11.08 Hz), 5.48 (m, 2H), 5.35 (tdd, 1H, J=1.56, 8.59, 10.94 Hz), 4.41 (ddd, 1H, J=1.17, 4.10, 8.79 
Hz), 2.97-3.00 (m, 1H), 2.86-2.81 (m, 3H), 2.34-2.31 (m, 2H), 2.28 (t, 2H, 7.23 Hz), 2.13-2.07 (m, 4H), 
1.95-1.89 (m, 1H), 1.77-1.71 (m, 1H), 1.66 (qint, 2H, 7.23 Hz), 1.41-1.36 (m, 2H), 1,31-1.28 (br m, 4H), 
0.90 (t, 3H, 7.0 Hz). Panel B.  1H NMR (BENZENE-d6/METHANOL-d4 90:10, 700 MHz) δ 5.51-5.43 (m, 
2H), 5.36-5.29 (m, 2H), 4.48 (dd, 1H, J=7.75, 4.0 Hz), 3.03 (dt, 1H, J=2.20, 5.1 Hz), 2.83 (dd, 1H, J=2.13, 
3.83 Hz), 2.65 (dt, 1H, J=2.25, 5.20 Hz), 2.61 (dt, 1H, J=2.21, 5.36 Hz), 2.14-2.05 (m, 2H), 2.02-
1.85 (m, 4H), 1.72-1.63 (dt, 1H, J=15.03, 4.58 Hz), 1.58-1.48 (m, 3H), 1.31-1.10 (m, 8H), 0.81 
(t, 3H, J=6.9 Hz) 
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Figure 6. H-NMR data of the synthetic lipid continued Panel A. Region of epoxy protons 1H 
NMR (BENZENE-d6/METHANOL-d4 90:10, 700 MHz) δ 3.04-3.01 (dt, 1H, J=2.20, 5.1 Hz), 2.84-
2.83 (dd, 1H, J=2.13, 3.83 Hz), 2.66-2.64 (dt, 1H, J=2.25, 5.20 Hz), 2.62-2.60 (dt, 1H, J=2.21, 5.36 Hz)  
 Panel B. 2D COSY. Panel C Structure of the synthetic generated diEHEDE isomer. (±)8,9-trans-
11(R),12(R)-trans-DiEp-13(R)-HEDE.  Panel D. Structure of the proposed platelet lipid 8,9-11,12-DiEp-
13-HEDE.  Shown here is the isomer proposed based on studies using mutant COX-2 isoforms: 8(R),9(R)-
cis-11(R),12(R)-trans-diEp-13(R)-HEDE.   
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Figure 7. DiEpHEDE activates neutrophil Mac-1 expression.   Panel B. DiEpHEDE activates human 
neutrophil Mac-1 expression.  Neutrophils were incubated with synthetic DiEpHEDE or vehicle, for 20 
min at 37 °C, and Mac-1 expression monitored by flow cytometry using anti-human CD11b (Mac-1)-Alexa 
Fluor 647. Where stated, neutrophils were pre-incubated with 10 µM synthetic DiEpHEDE or vehicle for 
10 min at 37 °C, and then activated with 10 µM fMLP for a further 10 min at 37 °C. Panel A. Bar chart 
showing activation of Mac-1 expression by DiEpHEDE . Data represent fold change in fluorescent signal 
normalized to vehicle control (n = 3 mean ± SEM). Statistical significance used one-way ANOVA 
followed by Bonferroni Post Hoc Test,*, p < 0.05. Panel B. Representative histogram depicting increased 
Mac-1 expression following activation with DiEpHEDE. Line represents the Mac-1-positive neutrophil 
gate, as set using untreated neutrophils.  
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Figure 8. Proposed route to synthesis of 8,9-11,12-DiEp-13-HEDE by COX isoforms.  
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